European Lifestars Awards - Celebrating Life Science Leaders’ Post

Leading Through Biotech's Perfect Storm: Lessons From The Front Lines https://lnkd.in/e2AA58mn - By Erik van den Berg, CEO, Memo Therapeutics AG

Leading Through Biotech's Perfect Storm: Lessons From The Front Lines https://lnkd.in/e2AA58mn - By Erik van den Berg, CEO, Memo Therapeutics AG

Check out the latest biotech industry news, from new sequencers and assays for drug optimization to the increasing interest in extracellular vesicles and the finances behind biotech >>> https://lnkd.in/eXTx2v8B Thermo Fisher Scientific, PacBio, Rousselot, Cytek Biosciences, Mursla Bio and Indaptus Therapeutics, Inc.

In the October edition of LifeLines, we highlighted member companies driving the latest advancements in AI and drug discovery, including BigHat Biosciences, Genesis Therapeutics, insitro and more. Read the story here: https://bit.ly/40y9yIH

Following a truly insight-rich discussion last week with Nicola McCarthy and Namshik Han of the Milner Therapeutics Institute and Biorelate's CSO Ben Sidders, you can now access the recorded webinar >> https://lnkd.in/eZsq-25A #drugdiscovery #artificialintelligence #bioinformatics

Building causal hypotheses in drug discovery 🎥🤔 If you missed last week's panel discussion with our own Nicola McCarthy and Namshik Han, and Biorelate's Ben Sidders and Daniel Jamieson, you can now view the recording online! Where are the opportunities to use AI and data driven approaches to create more robust models for developing actionable hypotheses? How can biopharma make better use of data for developing mechanistic rationales that will improve drug discovery outcomes for drug developers and patients? Join the discussion by clicking here 👉 https://lnkd.in/eZsq-25A

SDBN Trending News: Exclusive: Avenzo picks up another ADC, this time with multi-partnered DualityBio https://lnkd.in/gmZYEAax Avenzo Therapeutics, a well-funded biotech that has in-licensed treatment candidates from Chinese drug developers, has forged its third deal since reassembling much of the Turning Point Therapeutics crew. Athena Countouriotis’ San Diego biotech is tapping [...]

🎙In our newest #RunningThroughWalls episode, Nimish Shah speaks with Mirador Therapeutics Chairman and CEO Mark McKenna about the beginning of Mirador, what he learned from his time at Prometheus, what he values in a team and more. Listen here: https://vnrk.co/3KxobCR 

Longitude portfolio company Vera Therapeutics, Inc. has shown the effect of atacicept on kidney function in patients with immunoglobulin A nephropathy (IgAN) persists out to 96 weeks. The durability of the effects seen in the phase 2b trial led Evercore ISI analysts to say “this feels like a ‘functional cure’," reports Nick Paul Taylor in Fierce Biotech. Read more about atacicept's data at https://lnkd.in/eVZxWxdz #Biotech

BCBN Feed: Aviceda raises $207M series C to take geographic atrophy drug through phase 3 https://lnkd.in/g89UGfYs Aviceda Therapeutics has secured $207.5 million in series C funds as the immunomodulator-focused biotech awaits a phase 3 readout this year for its lead eye disease drug. The round was co-led by the healthcare funds Omega Funds and TCGX, with participation from other investors such as Enavate Sciences,... ... [...]